ArticleBiomaterials2012
Endosomal escape and siRNA delivery with cationic shell crosslinked knedel-like nanoparticles with tunable buffering capacities.
Article in Biomaterials, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 77 citations in OpenAlex.
- Evaluation of curcumin nanoparticles of various sizes for targeting multidrug-resistant lung cancer cells via inhalation.Nanomedicine (London, England) · 2025Article
- Nanomicellar Formulations Loaded with Histamine and Paclitaxel as a New Strategy to Improve Chemotherapy for Breast Cancer.International journal of molecular sciences · 2023Article
- Leveraging Electrostatic Interactions for Drug Delivery to the Joint.Bioelectricity · 2020Review
- Direct Drug Targeting into Intracellular Compartments: Issues, Limitations, and Future Outlook.The Journal of membrane biology · 2019Review
- Development of Fully Degradable Phosphonium-Functionalized Amphiphilic Diblock Copolymers for Nucleic Acids Delivery.Biomacromolecules · 2018Article
- Human Albumin Fragments Nanoparticles as PTX Carrier for Improved Anti-cancer Efficacy.Frontiers in pharmacology · 2018Article
- Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Discovery of a new function of curcumin which enhances its anticancer therapeutic potency.Scientific reports · 2016Article
- Polysaccharide-based nanoparticles for theranostic nanomedicine.Advanced drug delivery reviews · 2016Review
- Reductively Responsive Hydrogel Nanoparticles with Uniform Size, Shape, and Tunable Composition for Systemic siRNA Delivery in Vivo.Molecular pharmaceutics · 2015Article
- Data Mining as a Guide for the Construction of Cross-Linked Nanoparticles with Low Immunotoxicity via Control of Polymer Chemistry and Supramolecular Assembly.Accounts of chemical research · 2015Article
- Histamine-functionalized copolymer micelles as a drug delivery system in 2D and 3D models of breast cancer.Journal of materials chemistry. B · 2015Article
- Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers.Biomaterials · 2015Article
- Precisely tunable engineering of sub-30 nm monodisperse oligonucleotide nanoparticles.Journal of the American Chemical Society · 2014Article
- Differential immunotoxicities of poly(ethylene glycol)- vs. poly(carboxybetaine)-coated nanoparticles.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Surface charges and shell crosslinks each play significant roles in mediating degradation, biofouling, cytotoxicity and immunotoxicity for polyphosphoester-based nanoparticles.Scientific reports · 2013Article
- Shell-crosslinked knedel-like nanoparticles induce lower immunotoxicity than their non-crosslinked analogs.Journal of materials chemistry. B · 2013Article
- Cytokines as biomarkers of nanoparticle immunotoxicity.Chemical Society reviews · 2013Review
- Multifunctional hierarchically assembled nanostructures as complex stage-wise dual-delivery systems for coincidental yet differential trafficking of siRNA and paclitaxel.Nano letters · 2013Article
- Degradable cationic shell cross-linked knedel-like nanoparticles: synthesis, degradation, nucleic acid binding, and in vitro evaluation.Biomacromolecules · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Cationic shell crosslinked knedel-like nanoparticles (cSCKs) have emerged as a highly efficient transfection agent for nucleic acids delivery. In this study, a new class of cSCKs with tunable buffering capacities has been developed by altering the amounts of histamines and primary amines incorporated into their crosslinked shell regions. The effect of histamine content of these nanoparticles with a hydrodynamic diameter of ca. 20 nm, on the siRNA-binding affinity, cytotoxicity, immunogenicity, and transfection efficiency was investigated. The modification of cSCKs with histamine was found to reduce the siRNA-binding affinity and cellular binding. On the other hand, it significantly reduced the toxicity and immunogenicity of the nanoparticles with subsequent increase in the transfection efficiency. In addition, escape from endosomes was facilitated by having two species of low and high pK(a)s (i.e. histamine and primary amine groups, respectively), as demonstrated by the potentiometric titration experiments and the effect of bafilomycin A1, an inhibitor of the endosomal acidification, on the transfection efficiency of cSCKs. Histamine modification of 15 mol% was a threshold, above which cSCKs with higher histamine content completely lost the ability to bind siRNA and to transfect cells. This study highlights the potential of histamine incorporation to augment the gene silencing activity of cationic nanoparticles, reduce their toxicity, and increase their biocompatibility, which is of particular importance in the design of nucleic acids delivery vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.